Internal Reference Number: FOI_8197
Date Request Received: 09/10/2024 00:00:00
Date Request Replied To: 23/10/2024 00:00:00
This response was sent via: By Email
Request Summary: Breast Cancer
Request Category: Researcher
| Question Number 1: How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies: • Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Abemaciclib + Fulvestrant • Alpelisib + Fulvestrant • Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide • Aromatase Inhibitor as a single agent • Atezolizumab • Capecitabine as a single agent • Carboplatin + Paclitaxel • Eribulin as a single agent or in combination • Everolimus + Exemestane • Fulvestrant as a single agent • Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Palbociclib + Fulvestrant • Parp Inhibitors (Olaparib/Talazoparib) • Pembrolizumab • Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Ribociclib + Fulvestrant • Sacituzumab Govitecan • Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent • Transtuzumab deruxtecan • Trastuzumab as a single agent or in combination • Trastuzumab emtansine • Any other active systemic anti-cancer therapy | |
| Answer To Question 1: • Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) 17 • Abemaciclib + Fulvestrant <5 • Alpelisib + Fulvestrant 0 • Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide <5 • Aromatase Inhibitor as a single agent unable to answer- only combination treatment prescribed on Aria and usually patients will get this from their GP. • Atezolizumab 0 • Capecitabine as a single agent 6 • Carboplatin + Paclitaxel <5 • Eribulin as a single agent or in combination <5 • Everolimus + Exemestane <5 • Fulvestrant as a single agent 0 • Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) 28 • Palbociclib + Fulvestrant <5 • Parp Inhibitors (Olaparib/Talazoparib) <5 • Pembrolizumab <5 • Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) 13 • Ribociclib + Fulvestrant <5 • Sacituzumab Govitecan <5 • Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent <5 • Transtuzumab deruxtecan 5 • Trastuzumab as a single agent or in combination 39 • Trastuzumab emtansine <5 • Any other active systemic anti-cancer therapy 23 | |
| Question Number 2: Does your trust participate in any clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part. | |
| Answer To Question 2: SA¹ú¼Ê´«Ã½ is currently hosting fewer than 5 breast cancer research studies defined by IRAS as clinical trials. | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
